急诊科静脉利多卡因镇痛的安全性与有效性:一项系统评价
该系统评价检索了截至2017年1月的随机对照试验和观察性研究,评估静脉利多卡因在急诊成人急慢性疼痛中的安全性和有效性。共纳入8项研究、536例患者,因临床异质性和低质量未能进行Meta分析。6项随机对照试验中,2项显示静脉利多卡因镇痛效果与活性对照相当,2项优于活性对照,对肾绞痛和危重肢体缺血疼痛的疼痛评分降低程度与静脉吗啡相当或更高;2项研究显示对偏头痛无效。6项研究在225例接受静脉利多卡因的患者中报告20例不良事件,19例非严重、1例严重,任何不良事件发生率8.9%(95%CI 5.5%至13.4%),严重不良事件发生率0.4%(95%CI 0%至2.5%)。由于方法学局限,证据置信度极低。
要点
- 在急诊成人肾绞痛和危重肢体缺血疼痛中,静脉利多卡因的疼痛评分降低程度与静脉吗啡相当或更高。
- 静脉利多卡因对急诊偏头痛在2项研究中似乎无效。
- 225例接受静脉利多卡因的急诊患者中报告20例不良事件,其中19例非严重、1例严重,任何不良事件发生率8.9%(95%CI 5.5%至13.4%)。
- 严重不良事件发生率0.4%(95%CI 0%至2.5%),安全性数据有限。
- 证据置信度极低,因偏倚风险、不一致性和不精确性,未进行Meta分析。
适用人群与场景
- 急诊科接受疼痛管理的成人急性和慢性疼痛患者。
研究设计与关键结果
- 研究类型为系统评价,检索Ovid CENTRAL、Ovid EMBASE和Ovid MEDLINE从建库至2017年1月,纳入随机对照试验和观察性研究,共8项研究、536例患者。
- 6项随机对照试验中,静脉利多卡因在2项研究中镇痛效果与活性对照相当,在2项研究中优于活性对照。
- 静脉利多卡因对肾绞痛和危重肢体缺血疼痛的疼痛评分降低程度与静脉吗啡相当或更高。
- 2项研究显示静脉利多卡因对偏头痛似乎无效。
- 6项研究在225例接受静脉利多卡因的患者中报告20例不良事件,19例非严重、1例严重,任何不良事件发生率8.9%(95%CI 5.5%至13.4%),严重不良事件发生率0.4%(95%CI 0%至2.5%)。
- 因显著临床异质性和研究质量低,未进行Meta分析。
证据类型、等级与局限
- 证据类型为系统评价,纳入随机对照试验和观察性研究。
- 采用Cochrane协作工具和改良Newcastle-Ottawa量表评估偏倚风险,采用GRADE方法评估证据置信度。
- 因方法学局限包括偏倚风险、不一致性和不精确性,证据置信度极低。
- 局限:显著临床异质性和研究质量低妨碍了Meta分析。
对床旁实践的改变
- 当前证据有限,不足以界定静脉利多卡因在急诊急性肾绞痛和危重肢体缺血疼痛镇痛中的作用。
- 静脉利多卡因对其他适应证的疗效尚未得到充分检验。
- 静脉利多卡因用于急诊疼痛管理的安全性尚未得到充分检验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: We evaluate the safety and efficacy of intravenous lidocaine in adult patients with acute and chronic pain who are undergoing pain management in the emergency department (ED).
METHODS: We searched Ovid CENTRAL, Ovid EMBASE, and Ovid MEDLINE databases for randomized controlled trials and observational studies from inception to January 2017. Efficacy outcomes included reduction in pain scores from baseline to postintervention and need for rescue analgesia. Safety outcomes included incidence of serious (eg, cardiac arrest) and nonserious (eg, dizziness) adverse events. We used the Cochrane Collaboration tool and a modified Newcastle-Ottawa Scale to evaluate the risk of bias across studies. The Grading of Recommendations Assessment, Development and Evaluation approach was used to evaluate the confidence in the evidence available.
RESULTS: From a total of 1,947 titles screened, 61 articles were selected for full-text review. Eight studies met the inclusion criteria and underwent qualitative analysis, including 536 patients. The significant clinical heterogeneity and low quality of studies precluded a meta-analysis. Among the 6 randomized controlled trials included, intravenous lidocaine had efficacy equivalent to that of active controls in 2 studies, and was better than active controls in 2 other studies. In particular, intravenous lidocaine had pain score reduction comparable to or higher than that of intravenous morphine for pain associated with renal colic and critical limb ischemia. Lidocaine did not appear to be effective for migraine headache in 2 studies. There were 20 adverse events reported by 6 studies among 225 patients who received intravenous lidocaine in the ED, 19 nonserious and 1 serious (rate 8.9%, 95% confidence interval 5.5% to 13.4% for any adverse event; and 0.4%, 95% confidence interval 0% to 2.5% for serious adverse events). The confidence in the evidence available for the outcomes evaluated was deemed to be very low because of methodological limitations, including risk of bias, inconsistency, and imprecision.
CONCLUSION: There is limited current evidence to define the role of intravenous lidocaine as an analgesic for patients with acute renal colic and critical limb ischemia pain in the ED. Its efficacy for other indications has not been adequately tested. The safety of lidocaine for ED pain management has not been adequately examined.
参考来源
- E Silva LOJ, Scherber K, Cabrera D, et al. Safety and Efficacy of Intravenous Lidocaine for Pain Management in the Emergency Department: A Systematic Review. Ann Emerg Med. 2018. PMID: 29395284. doi:10.1016/j.annemergmed.2017.12.014
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。